ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

Combination Therapy:
The combination of Imfinzi (durvalumab) and Imjudo (tremelimumab) has shown significant improvement in the treatment of advanced liver cancer, specifically unresectable hepatocellular carcinoma (HCC).

5-Year Survival Rate:
The combination therapy has doubled the 5-year overall survival rate in patients with advanced liver cancer, marking a significant breakthrough in the treatment of this aggressive disease.

HIMALAYA Trial:
The HIMALAYA Phase III trial demonstrated that the combination of Imfinzi and Imjudo reduced the risk of death by 22% compared to sorafenib, a standard-of-care multi-kinase inhibitor.

Safety Profile:
The safety profiles of the combination therapy and Imfinzi alone were consistent with their known profiles, with no new safety signals identified.

Regulatory Approval:
The combination of Imfinzi and Imjudo has been approved in the US, EU, Japan, and several other countries for the treatment of adults with advanced or unresectable HCC.

Impact on Patients:
This approval provides a new, innovative therapeutic option for patients with unresectable liver cancer, improving long-term survival and addressing a critical unmet need in this patient population.

AstraZeneca's Vision:
AstraZeneca aims to redefine cancer care and eliminate cancer as a cause of death through persistent innovation and the development of life-changing medicines.